Edward Wenge Wang, M.D., Ph.D.
Edward Wenge Wang, M.D., Ph.D., is an assistant professor in the Department of Medical Oncology & Therapeutics Research, specializing in gynecologic oncology.
Dr. Wang earned his undergraduate degree in medicine, followed by a Master of Science degree in immunology and a Ph.D. in tumor immunology, from Harbin Medical University in Harbin, China. He completed postdoctoral research at Columbia University Vagelos College of Physicians and Surgeons in New York, before moving to Philadelphia to serve as a research associate at the Howard Hughes Medical Institute, while also serving as senior research investigator at the University of Pennsylvania School of Medicine.
After a brief time as director of projects for the Hershey Cancer Institute at Penn State University Hershey Medical College, Dr. Wang successfully completed postgraduate training with an internship and residency in internal medicine at Montefiore Mount Vernon Hospital in New York, and Banner-University Medical Center in Phoenix, respectively. He completed his hematology-oncology fellowship training at Penn State Hershey Medical College in Pennsylvania.
Dr. Wang has authored 45 scholarly articles and has been an invited lecturer at symposiums and conferences across the country. He is a principal investigator of several clinical trials. He is running a Molecular and Cellular Laboratory in the City of Hope Biomedical Research Center at Beckman Research Institute of City of Hope for translational research. His research interests include: Targeting intrinsic and extrinsic cell death pathways by developing novel therapeutics for cancer treatment. Most recently, he has developed an oncolytic virus that can specifically replicate in and lyse gynecological cancer cells.
In 2002, Dr. Wang received the AACR/AFLAC Scholar-in-Training Award at the American Association for Cancer Research Annual Meeting in San Francisco.
Dr. Wang is the recipient of several intramural and extramural grants including an NIH K12 career development award in 2018, an NIH/NCI R21 grant in 2021, for ovarian cancer research.
2016, American Society of Clinical Oncology Board certified
2016, American Society of Hematology Board eligible
2013, American Board of Internal Medicine certified
1988, B.M., Medicine, Habin Medical University, Harbin, Heilongjiang, China
1991, M.S., Immunology, Harbin Medical University, Harbin, Heilongjiang, China
1994, Ph.D., Tumor Immunology, Harbin Medical University, Heilongjiang, China
2013-2016, Fellow, Hematology/Oncology, Penn State Hershey Medical Center, Hershey, PA
2011-2013, Resident, Categorical Internal Medicine, Banner University Medical Center, University Medical Center, Phoenix, AZ
2010-2011, Intern, Categorical Internal Medicine, Montefiore Mount Vernon Hospital, Mount Vernon, NY
2019-present, Associate Editor, Frontiers in Oncology: Cancer Molecular Targets and Therapeutics, a peer-reviewed professional journal
2018-present, Editor, Cancer Biology and Therapy, a peer-reviewed professional journal
2016-present, Assistant Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, CA
2017-2021, NIH/NCI: K12 Fellow, Paul Calabresi Career Development Award for Clinical Oncology
2010, Director of Research Projects, Cancer Institute, Penn State Hershey Medical Center, Hershey, PA
2004-2010, Senior Research Investigator, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
2001-2004, Research Associate, Howard Hughes Medical Institute, University of Pennsylvania, Philadelphia, PA
1999-2001, Postdoctoral Research Scientist, Columbia University Vagelos College of Physicians and Surgeons, New York, NY
1997-1999, International Special Medical Investigator, Japan Society for Promotion of Science, Osaka University Medical School, Osaka, Japan
1994-1997, Postdoctoral Research Fellow, Department of Experimental Hematology, Beijing Medical Academy Institute of Radiology, Beijing, China
Member, American Society of Clinical Oncology
Member, American Society of Hematology
Member, American Association Cancer Research
Review Articles, Editorials and Case Reports
- Wang EW, Wei CH, Liu S, Lee SJ, Shehayeb S, Glaser S, Li R, Saadat S, Shen J, Dellinger T, Han ES, Stewart D, Wilczynski S, Cristea M, Rodriguez-Rodriguez L. Frontline Management of Epithelial Ovarian Cancer-Combining Clinical Expertise with Community Practice Collaboration and Cutting-Edge Research. J Clin Med. 2020 Sep 1;9(9). doi: 10.3390/jcm9092830. Review. PubMed PMID: 32882942; PubMed Central PMCID: PMC7565288.
- Yin M, Wang W, Drabick JJ, Harold HA. Prognosis and treatment of non-metastatic primary and secondary breast angiosarcoma: a comparative study. BMC Cancer. 2017 Apr 27;17(1):295. doi: 10.1186/s12885-017-3292-7. PubMed PMID: 28449661; PubMed Central PMCID: PMC5408408.
- Yin M, Wang W, Rosenberg J, Kaag M, Joshi M, Holder S, Tuanquin L, Drabick JJ. Targeted Therapy in Collecting Duct Carcinoma of the Kidney: A Case Report and Literature Review. Clin Genitourin Cancer. 2016 Apr;14(2):e203-6. doi: 10.1016/j.clgc.2015.11.008. Epub 2015 Nov 17. Review. PubMed PMID: 26684811.
- Koller KM, Wang W, Schell TD, Cozza EM, Kokolus KM, Neves RI, Mackley HB, Pameijer C, Leung A, Anderson B, Mallon CA, Robertson G, Drabick JJ. Malignant melanoma-The cradle of anti-neoplastic immunotherapy. Crit Rev Oncol Hematol. 2016 Oct;106:25-54. doi: 10.1016/j.critrevonc.2016.04.010. Epub 2016 May 7. Review. PubMed PMID: 27637351.
- Wang W, Cheng J, Mallon C, Al-Marrawi MY, Holder S, Joshi M, Kaag M, Talamo G, Drabick JJ. Symptomatic Secondary Polycythemia Induced by Anti-VEGF Therapy for the Treatment of Metastatic Renal Cell Carcinoma: A Case Series and Review. Clin Genitourin Cancer. 2015 Dec;13(6):e391-5. doi: 10.1016/j.clgc.2015.07.003. Epub 2015 Jul 26. Review. PubMed PMID: 26303589.
- Chen F, Wang W, El-Deiry WS. Current strategies to target p53 in cancer. Biochem Pharmacol. 2010 Sep 1;80(5):724-30. doi: 10.1016/j.bcp.2010.04.031. Epub 2010 May 5. Review. PubMed PMID: 20450892.
- Bassett EA, Wang W, Rastinejad F, El-Deiry WS. Structural and functional basis for therapeutic modulation of p53 signaling. Clin Cancer Res. 2008 Oct 15;14(20):6376-86. doi: 10.1158/1078-0432.CCR-08-1526. Review. PubMed PMID: 18927276.
- Wang W, El-Deiry WS. Restoration of p53 to limit tumor growth. Curr Opin Oncol. 2008 Jan;20(1):90-6. doi: 10.1097/CCO.0b013e3282f31d6f. Review. PubMed PMID: 18043262.
- Wang W, El-Deiry WS. Targeting p53 by PTD-mediated transduction. Trends Biotechnol. 2004 Sep;22(9):431-4. doi: 10.1016/j.tibtech.2004.07.002. PubMed PMID: 15331219.
- Wang W, El-Deiry WS. Targeting FOXO kills two birds with one stone. Chem Biol. 2004 Jan;11(1):16-8. doi: 10.1016/j.chembiol.2004.01.011. PubMed PMID: 15112990.
- Wang W, Rastinejad F, El-Deiry WS. Restoring p53-dependent tumor suppression. Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S55-63. Review. PubMed PMID: 14508081.
Original, Peer-Reviewed Research Articles
- Liang R, Yao Y, Wang G, Yue E, Yang G, Qi X, Wang Y, Zhao L, Zheng T, Zhang Y, Wenge Wang E. Repositioning Quinacrine Toward Treatment of Ovarian Cancer by Rational Combination With TRAIL. Front Oncol. 2020;10:1118. doi: 10.3389/fonc.2020.01118. eCollection 2020. PubMed PMID: 32766144; PubMed Central PMCID: PMC7379129.
- Wang J, Mirzapoiazova T, Carol Tan YH, Pang KM, Pozhitkov A, Wang Y, Wang Y, Mambetsariev B, Wang E, Nasser MW, Batra SK, Raz D, Reckamp K, Kulkarni P, Zheng Y, Salgia R. Inhibiting crosstalk between MET signaling and mitochondrial dynamics and morphology: a novel therapeutic approach for lung cancer and mesothelioma. Cancer Biol Ther. 2018;19(11):1023-1032. doi: 10.1080/15384047.2018.1472193. Epub 2018 Oct 12. PubMed PMID: 30311833; PubMed Central PMCID: PMC6301806.
- Shinde A, Li R, Amini A, Chen YJ, Cristea M, Dellinger T, Wang W, Wakabayashi M, Beriwal S, Glaser S. Improved survival with adjuvant brachytherapy in stage IA endometrial cancer of unfavorable histology. Gynecol Oncol. 2018 Oct;151(1):82-90. doi: 10.1016/j.ygyno.2018.08.028. Epub 2018 Aug 28. PubMed PMID: 30170976.
- Dower CM, Bhat N, Wang EW, Wang HG. Selective Reversible Inhibition of Autophagy in Hypoxic Breast Cancer Cells Promotes Pulmonary Metastasis. Cancer Res. 2017 Feb 1;77(3):646-657. doi: 10.1158/0008-5472.CAN-15-3458. Epub 2016 Nov 15. PubMed PMID: 28115361; PubMed Central PMCID: PMC5300746.
- Allen JE, Krigsfeld G, Mayes PA, Patel L, Dicker DT, Patel AS, Dolloff NG, Messaris E, Scata KA, Wang W, Zhou JY, Wu GS, El-Deiry WS. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci Transl Med. 2013 Feb 6;5(171):171ra17. doi: 10.1126/scitranslmed.3004828. PubMed PMID: 23390247; PubMed Central PMCID: PMC4535715.
- Zhou L, El-Deiry W, Wang W, Ingram ME, Katz SI. Extracellular protease imaging for cell mass tracking of xenografted human malignant pleural mesothelioma. Oncol Rep. 2012 Sep;28(3):883-8. doi: 10.3892/or.2012.1888. Epub 2012 Jun 26. PubMed PMID: 22751990.
- Zhou L, Wang W, Dicker DT, Humphreys RC, El-Deiry WS. Prediction of proapoptotic anticancer therapeutic response in vivo based on cell death visualization and TRAIL death ligand-receptor interaction. Cancer Biol Ther. 2011 Aug 15;12(4):335-48. doi: 10.4161/cbt.12.4.17174. Epub 2011 Aug 15. PubMed PMID: 21785270.
- Gallant JN, Allen JE, Smith CD, Dicker DT, Wang W, Dolloff NG, Navaraj A, El-Deiry WS. Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer. Cancer Biol Ther. 2011 Aug 1;12(3):239-51. doi: 10.4161/cbt.12.3.17034. Epub 2011 Aug 1. PubMed PMID: 21725213.
- Wang W, Gallant JN, Katz SI, Dolloff NG, Smith CD, Abdulghani J, Allen JE, Dicker DT, Hong B, Navaraj A, El-Deiry WS. Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents. Cancer Biol Ther. 2011 Aug 1;12(3):229-38. doi: 10.4161/cbt.12.3.17033. Epub 2011 Aug 1. PubMed PMID: 21725212.
- Katz SI, Zhou L, Ferrara TA, Wang W, Mayes PA, Smith CD, El-Deiry WS. FLT-PET may not be a reliable indicator of therapeutic response in p53-null malignancy. Int J Oncol. 2011 Jul;39(1):91-100. doi: 10.3892/ijo.2011.1019. Epub 2011 Apr 29. PubMed PMID: 21537838.
- Dews M, Fox JL, Hultine S, Sundaram P, Wang W, Liu YY, Furth E, Enders GH, El-Deiry W, Schelter JM, Cleary MA, Thomas-Tikhonenko A. The myc-miR-17~92 axis blunts TGF{beta} signaling and production of multiple TGF{beta}-dependent antiangiogenic factors. Cancer Res. 2010 Oct 15;70(20):8233-46. doi: 10.1158/0008-5472.CAN-10-2412. Epub 2010 Oct 12. PubMed PMID: 20940405; PubMed Central PMCID: PMC3007123.
- McGovern PE, Christofidou-Solomidou M, Wang W, Dukes F, Davidson T, El-Deiry WS. Anticancer activity of botanical compounds in ancient fermented beverages (review). Int J Oncol. 2010 Jul;37(1):5-14. doi: 10.3892/ijo_00000647. Review. PubMed PMID: 20514391.
- Katz SI, Zhou L, Chao G, Smith CD, Ferrara T, Wang W, Dicker DT, El-Deiry WS. Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma. Cancer Biol Ther. 2009 Dec;8(24):2406-16. doi: 10.4161/cbt.8.24.10824. Epub 2009 Dec 2. PubMed PMID: 20038816; PubMed Central PMCID: PMC3052759.
- Allen JE, Hart LS, Dicker DT, Wang W, El-Deiry WS. Visualization and enrichment of live putative cancer stem cell populations following p53 inactivation or Bax deletion using non-toxic fluorescent dyes. Cancer Biol Ther. 2009 Nov;8(22):2194-205. doi: 10.4161/cbt.8.22.10450. Epub 2009 Nov 27. PubMed PMID: 19923899; PubMed Central PMCID: PMC2975270.
- Huang C, Zhang XM, Tavaluc RT, Hart LS, Dicker DT, Wang W, El-Deiry WS. The combination of 5-fluorouracil plus p53 pathway restoration is associated with depletion of p53-deficient or mutant p53-expressing putative colon cancer stem cells. Cancer Biol Ther. 2009 Nov;8(22):2186-93. doi: 10.4161/cbt.8.22.10446. Epub 2009 Nov 27. PubMed PMID: 19923910; PubMed Central PMCID: PMC4541801.
- Kuribayashi K, Krigsfeld G, Wang W, Xu J, Mayes PA, Dicker DT, Wu GS, El-Deiry WS. TNFSF10 (TRAIL), a p53 target gene that mediates p53-dependent cell death. Cancer Biol Ther. 2008 Dec;7(12):2034-8. doi: 10.4161/cbt.7.12.7460. PubMed PMID: 19106633.
- Lu C, Wang W, El-Deiry WS. Non-genotoxic anti-neoplastic effects of ellipticine derivative NSC176327 in p53-deficient human colon carcinoma cells involve stimulation of p73. Cancer Biol Ther. 2008 Dec;7(12):2039-46. doi: 10.4161/cbt.7.12.7461. PubMed PMID: 19106635; PubMed Central PMCID: PMC3626664.
- Laguinge LM, Samara RN, Wang W, El-Deiry WS, Corner G, Augenlicht L, Mishra L, Jessup JM. DR5 receptor mediates anoikis in human colorectal carcinoma cell lines. Cancer Res. 2008 Feb 1;68(3):909-17. doi: 10.1158/0008-5472.CAN-06-1806. PubMed PMID: 18245494.
- Ricci MS, Kim SH, Ogi K, Plastaras JP, Ling J, Wang W, Jin Z, Liu YY, Dicker DT, Chiao PJ, Flaherty KT, Smith CD, El-Deiry WS. Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell. 2007 Jul;12(1):66-80. doi: 10.1016/j.ccr.2007.05.006. PubMed PMID: 17613437.
- Yang W, Rozan LM, McDonald ER 3rd, Navaraj A, Liu JJ, Matthew EM, Wang W, Dicker DT, El-Deiry WS. CARPs are ubiquitin ligases that promote MDM2-independent p53 and phospho-p53ser20 degradation. J Biol Chem. 2007 Feb 2;282(5):3273-81. doi: 10.1074/jbc.M610793200. Epub 2006 Nov 22. PubMed PMID: 17121812.